Every 8-K that Voyager Therapeutics, Inc. (VYGR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VYGR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VYGR filings page.
Voyager Therapeutics reported second quarter 2026 results highlighted by continued investment in its neurology pipeline and lower operating expenses. Collaboration revenue was $3.2 million, down from $5.2 million a year earlier, mainly because revenue under the Neurocrine collaboration declined as activities moved beyond the research phase. Research and development expense fell to $22.0 million from $31.3 million, and general and administrative expense decreased to $7.5 million from $10.5 million, reflecting program prioritization and prior restructuring. Net loss narrowed to $24.5 million, or $0.40 per share, from $33.4 million, or $0.57 per share.
Cash, cash equivalents, and marketable securities were $148.8 million as of June 30, 2026. Based on current operating plans and anticipated collaboration reimbursements and interest income, management expects these resources to fund planned operating and capital spending into 2028.
Voyager continues to advance its Alzheimer’s disease programs, with tau-targeted antibody VY7523 expected to deliver tau PET imaging data in the fourth quarter of 2026 and tau-silencing gene therapy VY1706 expected to begin dosing in adults with early Alzheimer’s disease in the same period. Initial acute safety data for VY1706 are targeted for early 2027 and biomarker-based data for the second half of 2027, both subject to enrollment. Partner Neurocrine Biosciences intends to start a clinical trial of Friedreich’s ataxia gene therapy NBIB-‘223 in the second half of 2026, pending FDA IND clearance. Preclinical GLP toxicology data for VY1706 in non-human primates showed it was well tolerated with up to 75% tau reduction in key brain regions after a single IV dose.
Voyager Therapeutics, Inc. reported new good laboratory practice toxicology and pharmacology data for VY1706, its investigational tau silencing gene therapy for Alzheimer’s disease. In non-human primates, three- and six-month studies showed a favorable tolerability profile with no adverse clinical pathology or histopathological findings in the central nervous system, dorsal root ganglia, or peripheral organs, including liver, at doses up to 5 x 10^13 vector genomes/kilogram.
The data also showed that a single intravenous dose achieved broad, durable, dose-dependent CNS delivery with up to 75% reduction of MAPT mRNA and tau protein in key Alzheimer’s-relevant brain regions through six months. ALPL, a brain vasculature endothelial receptor, mediated blood-brain barrier transport, supporting potential cross-species translatability. Voyager previously received FDA Investigational New Drug clearance for VY1706 in June 2026 and plans first-in-human dosing in a multi-site, open-label, dose-escalation trial in the second half of 2026.
Voyager Therapeutics, Inc. reported results from its 2026 Annual Meeting of Stockholders and an amendment to its charter. Stockholders approved a Certificate of Amendment increasing authorized capital stock from 125,000,000 to 245,000,000 shares and authorized common stock from 120,000,000 to 240,000,000 shares. The additional common stock has the same rights as existing common shares, and the amendment became effective upon filing with the Delaware Secretary of State on June 9, 2026. Stockholders also elected directors and approved other meeting proposals based on the votes disclosed.
Voyager Therapeutics announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for VY1706, an investigational tau silencing gene therapy for Alzheimer’s disease. This clearance allows the company to start human testing.
The company plans a multi-site, open-label, dose-escalation trial beginning dosing in the second half of 2026. VY1706 will be given once by intravenous infusion to adults with early Alzheimer’s who show tau pathology on PET imaging. The study will enroll up to 18 patients across three dose cohorts, with the highest dose not exceeding 5 x 1013 vector genomes per kilogram.
The primary goal is to evaluate safety and tolerability. Secondary measures will look at effects on tau biology, including changes in cerebrospinal fluid tau biomarkers and tau pathology assessed by tau PET imaging. The company also highlights typical development risks and uncertainties that could affect timing, results, and future plans.
Voyager Therapeutics reported first quarter 2026 results and highlighted progress across its neurology pipeline. Collaboration revenue was $2.6 million, and the company recorded a net loss of $27.9 million, or $0.47 per share, compared with a $31.0 million loss a year earlier.
Research and development expenses fell to $24.6 million, and general and administrative costs declined to $8.3 million, reflecting lower operating spend. Voyager ended the quarter with $171.7 million in cash, cash equivalents and marketable securities, which it expects to fund operations into 2028.
On the pipeline, VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology studies, with clinical entry expected in the second half of 2026. The company also plans mid‑2026 third‑party tau data, first‑in‑human dosing of VY1706, and tau PET imaging efficacy data for antibody VY7523 in late 2026.
Voyager Therapeutics, Inc. announced a planned finance leadership transition. Chief Financial Officer Nathan Jorgensen, Ph.D. has decided to resign from his roles, effective May 8, 2026, to pursue a new opportunity, and the company states his departure does not stem from any disagreement.
Effective at the same time, long‑tenured executive Robin Swartz, currently Chief Operating Officer and Chief Business Officer, will become principal financial officer and treasurer. Amy Quinlan, the company’s Vice President of Finance, will become principal accounting officer and is expected to enter into Voyager’s standard indemnification agreement.
Voyager Therapeutics, Inc. reported fourth quarter and full year 2025 financial and operating results, highlighting pipeline progress in Alzheimer’s disease, intravenous gene therapies, and its Voyager NeuroShuttle™ platform. Collaboration revenue for 2025 was $40.4 million, down from $80.0 million in 2024, while net loss widened to $119.7 million from $65.0 million.
The company ended 2025 with $201.7 million in cash, cash equivalents, and marketable securities and expects this to fund operations into 2028, assuming planned expenses and anticipated collaboration reimbursements and interest income. Management also notes potential additional non-dilutive development milestones of up to $2.4 billion under existing collaborations.
Voyager Therapeutics, Inc. announced that Chief Medical Officer Toby Ferguson, M.D., Ph.D. has decided to resign from his role and all other positions with the company and its subsidiaries, effective February 20, 2026, to pursue a new opportunity.
The company states that Dr. Ferguson’s resignation is not due to any disagreement with Voyager. President and Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D. has agreed to assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis after the resignation becomes effective.
Voyager Therapeutics, Inc. filed a Form 8-K to inform investors that it has posted an updated corporate investor presentation on the Investors section of its website and will distribute a letter summarizing key points from that presentation to certain stockholders. These materials are included as Exhibits 99.1 and 99.2 and are furnished, rather than filed, meaning they are not automatically subject to certain Exchange Act liabilities or incorporated into other SEC filings unless specifically referenced. The materials and related forward-looking statements discuss Voyager’s preclinical and clinical development plans, potential expansion into additional neurogenetic medicine modalities, collaboration and licensing arrangements, and the expected sufficiency of its cash resources, all subject to significant scientific, regulatory, collaboration, and funding risks outlined in the company’s risk disclosures.
Voyager Therapeutics, Inc. filed a Form 8-K to report that it announced its third quarter 2025 financial results and corporate updates. The company did this by issuing a press release dated November 10, 2025, which is included with the filing as Exhibit 99.1 under Item 2.02.
The press release is treated as “furnished” rather than “filed,” meaning it is not automatically subject to certain Exchange Act liabilities and will only be incorporated into other securities filings if specifically referenced. The filing also identifies Voyager’s common stock, traded on the Nasdaq Global Select Market under the symbol VYGR, and is signed by Alfred Sandrock, M.D., Ph.D., the company’s Chief Executive Officer, President, and Director.
Voyager Therapeutics, Inc. furnished an investor presentation in connection with its appearance at Citi’s 2025 Biopharma Back to School Conference. The company plans to present the materials in Exhibit 99.1 on September 2, 2025 at 4:00 p.m. ET.
The presentation is being provided under Regulation FD and, along with Item 7.01, is treated as “furnished” rather than “filed,” which limits certain securities law liabilities and incorporation by reference. Voyager states it is not admitting the materiality of the information and notes that these materials should be read together with its other SEC filings and public disclosures, and it does not undertake an obligation to update them.